Claudia Lago Toro, MD
Surgical Oncology · Poughkeepsie, NYNPI 1659585131
Payments from drug & device makers
Across 34 payments — averaging $35.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Genetic Laboratories, Inc.$329
- Dilon Technologies, Inc.$313
- Kerecis Limited$85
- Hologic Inc$55
- Seagen Inc.$54
- Stryker$40
- plus $316 from 13 others
What the payments were for
- Food & beverage$1,191100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | 6 | $329 |
| Dilon Technologies, Inc. | 6 | $313 |
| Kerecis Limited | 2 | $85 |
| Hologic Inc | 1 | $55 |
| Seagen Inc. | 3 | $54 |
| Stryker | 1 | $40 |
| Hologic Sales And Service, LLC | 2 | $39 |
| Molli Surgical (US) Inc | 1 | $37 |
| Tactile Systems Technology Inc | 1 | $36 |
| Galderma Laboratories, L.p. | 2 | $33 |
| Cardinal Health 414 LLC | 1 | $24 |
| AbbVie | 1 | $24 |
| Tempus AI, Inc | 1 | $21 |
| Solventum Corporation | 1 | $21 |
| Novartis | 1 | $19 |
| Heron Therapeutics, Inc. | 1 | $19 |
| Smith+Nephew | 1 | $16 |
| TELA Bio, Inc. | 1 | $16 |
| Foundation Medicine, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myRisk$229
- HemoBlast Bellows$163
How this compares
$1,191 in reported general payments places this provider in the 50th percentile of 173 surgical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $77 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Poughkeepsie
- James NitzkorskiPoughkeepsie$50K
- Michael MinarichPoughkeepsie$14K
- Ryan SwanPoughkeepsie$11K
- Cliff ConneryPoughkeepsie$8K
- Huan Huan SunPoughkeepsie$8K
- Michael LoweNew York$814K
- George PlitasNew York$808K
- George MillerNew York$759K
- Mary KemenyJamaica$639K
- Lukasz CzerwonkaStony Brook$515K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.